Edwards Lifesciences Surges to 260th in Trading Volume with 4.26 Billion Shares Exchanged

On May 13, 2025, Edwards Lifesciences (EW) saw a significant increase in trading volume, with a total of 4.26 billion shares traded, marking a 50.91% rise from the previous day. This surge placed Edwards Lifesciences at the 260th position in terms of trading volume for the day. The stock price of Edwards Lifesciences (EW) rose by 0.94%, marking the second consecutive day of gains, with a total increase of 2.47% over the past two days.

Edwards Lifesciences has recently received positive analyst coverage, with Piper Sandler raising its price target to $83 from $80. Additionally, Canaccord and Baird have also increased their price targets to $75 from $71 and $75 from $72, respectively. Piper Sandler also upgraded Edwards Lifesciences to Overweight from Neutral, reflecting a bullish outlook on the company's prospects.

Edwards Lifesciences reported its first-quarter earnings, with EPS coming in at 61 cents, slightly above the consensus estimate of 60 cents. The company reaffirmed its fiscal year 2025 adjusted EPS guidance of $2.40-$2.50, which is in line with the consensus estimate of $2.45. Management also raised its FY25 TMTT revenue guidance by approximately 5% at the midpoint, while maintaining its overall company and TAVR revenue guidance ranges.

The company's performance was driven by better-than-expected TAVR growth and continued momentum in TMTT. The FDA approval of the SAPIEN 3 platform in asymptomatic patients is expected to unlock a large commercial opportunity for Edwards Lifesciences. However, challenges remain, including competitive pressure in Japan, hospital capacity constraints in the US, and concerns about the pricing environment for TAVR.